Financial Results - Standalone (Quarter ended June 30, 2026)

  • Total Income: ₹6.30 crores (Q1 FY27) vs ₹5.02 crores (Q4 FY26) vs ₹8.79 crores (Q1 FY26)
  • Revenue from Operations: ₹1.94 crores
  • Other Income: ₹4.36 crores
  • Total Expenses: ₹3.65 crores
  • Profit before tax and exceptional items: ₹2.65 crores
  • Exceptional items: (₹1.74) crores (related to warrant forfeiture)
  • Profit before tax: ₹0.91 crores
  • Tax expense: (₹0.13) crores (deferred tax)
  • Net Profit for the period: ₹1.04 crores
  • Total Comprehensive Income: ₹1.02 crores
  • Basic EPS: ₹0.44
  • Diluted EPS: ₹0.44

Financial Results - Consolidated (Quarter ended June 30, 2026)

  • Total Income: ₹227.61 crores
  • Revenue from Operations: ₹225.86 crores
  • Other Income: ₹1.75 crores
  • Total Expenses: ₹211.03 crores
  • Profit before tax and exceptional items: ₹16.58 crores
  • Exceptional items: (₹1.74) crores
  • Profit before tax: ₹14.84 crores
  • Tax expense: (₹0.13) crores
  • Net Profit for the period: ₹14.97 crores
  • Profit attributable to owners: ₹12.70 crores
  • Total Comprehensive Income attributable to owners: ₹11.98 crores
  • Basic EPS: ₹5.39
  • Diluted EPS: ₹5.39

Key Financial Notes

1. The Company has one reportable segment: "Pharma Packaging Research Solutions"

2. Accounts prepared on going-concern basis based on positive GCS business prospects

3. Transferred ₹2.93 crores to IEPF on 10th July 2026 as per NCLT order dated 5th June 2026

4. Asset held for sale with book value of ₹64.07 crores (land parcels)

5. Contingent liability: Penal interest of ₹18.55 crores on CSIR loan (matter subjudice)

6. During quarter: Paid ₹25.58 crores for 75% of 17,05,000 outstanding warrants; 3,15,000 warrants lapsed and ₹1.58 crores forfeited

7. SFIO investigation ongoing since MCA order dated 3 June 2020

Board Approvals

A. Changes in Directors

  • Appointment of Mr. Mohan Bhandari (DIN: 00052777) as Executive Director effective 13 August 2026, subject to shareholder approval. Term: 5 years. Shareholding: 5,856,489 equity shares (24.87%). He is promoter, founder and CEO of the company.
  • Reappointment of Ms. Kavita Bhansali as Executive Director for further 5 years effective 15 August 2026, subject to shareholder approval. Shareholding: Nil.

B. Changes in Key Managerial Personnel

  • Mr. Sagar R. Baheti resigned as Company Secretary, Compliance Officer and KMP on 13 August 2026, effective 24 September 2026 (personal reasons).
  • Mr. Mayur Dave appointed as Company Secretary, Compliance Officer and KMP effective 25 September 2026.

C. Subsidiary Update

  • Voluntary winding up of Bilcare INC (wholly owned US subsidiary) approved. The subsidiary had nil turnover in FY 2025-26 and is not material.

Auditor's Review

Patki and Soman Chartered Accountants issued limited review reports for both standalone and consolidated results, drawing attention to:

  • Going concern assumption based on management's positive outlook for GCS business
  • IEPF transfer of ₹2.93 crores completed
  • Assets held for sale classification
  • Contingent liability for penal interest on CSIR loan
  • Warrant conversion and forfeiture transactions
  • SFIO investigation status

Board Meeting Details

  • Date: 13 August 2026
  • Time: 4:30 PM to 8:30 PM (IST)